Sanofi S.A. (SNY)
| Market Cap | 135.34B |
| Revenue (ttm) | 45.57B |
| Net Income (ttm) | 15.02B |
| Shares Out | 2.50B |
| EPS (ttm) | 5.86 |
| PE Ratio | 9.18 |
| Forward PE | 14.25 |
| Dividend | $3.20 |
| Dividend Yield | 5.95% |
| Trading Day | June 11 |
| Last Price | $53.80 |
| Previous Close | $53.78 |
| Change ($) | 0.02 |
| Change (%) | 0.04% |
| Day's Open | 53.85 |
| Day's Range | 53.51 - 53.91 |
| Day's Volume | 872,656 |
| 52-Week Range | 43.13 - 54.19 |
Sanofi SA's (NASDAQ: SNY) sutimlimab nailed all three of its primary endpoints in its Phase 3 CADENZA study for patients with cold agglutinin disease. This rare disorder can cause severe anemia without ...
Sanofi CEO on breakthroughs in cancer research, COVID-19 vaccine development, and drug pricing
Sanofi CEO Paul Hudson joins Yahoo Finance's Anjalee Khemlani to discuss the company's cancer research, COVID-19 vaccine efforts, and drug pricing. Watch the 2021 Berkshire Hathaway Annual Shareholders ...
Sanofi SA (NASDAQ: SNY) has secured partners for a Phase 3 trial to study amcenestrant versus the hormone therapy tamoxifen in breast cancer. The Breast International Group (BIG), the European Organizat...
PARIS, June 4, 2021 /PRNewswire/ -- Sanofi is partnering with leading groups delivering practice-changing breast cancer research, the Breast International Group (BIG), the European Organization for Rese...
These Covid-19 vaccine stocks may be late in the race, but they certainly have growth potential as we head into the summer. The post 7 Best Vaccine Stocks for Their Pipeline Potential appeared first on ...
Sanofi l aunches € 3 million Planet Mobilization f und to support employees' environmental projects
Sanofi (SNY) discontinues development of pipeline candidate, venglustat, in patients with autosomal dominant polycystic kidney disease, following failure in a pivotal study.
Sanofi SA (NASDAQ: SNY) has halted the clinical program of venglustat in autosomal dominant polycystic kidney disease (ADPKD). Although the safety profile of venglustat remains consistent with previousl...
Sanofi provides update on venglustat clinical program
Sanofi (SNY) and Glaxo initiate phase III study to evaluate their adjuvanted COVID-19 vaccine candidate. A booster program will start soon.
One part of the trial will test the vaccine against the South African variant of the virus.
Sanofi and GSK initiate global Phase 3 clin i cal efficacy study of COVID-19 vaccine candidate
Mexico Foreign Minister Marcel Ebrard said that the country would begin phase 3 trials for COVID-19 vaccines by Sanofi SA (NASDAQ: SNY) and China's Walvax soon. Mexico's health regulator Cofepris approv...
Regeneron (REGN) and Sanofi's (SNY) Libtayo gets positive CHMP opinion for two additional indications.
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Libtayo...
It's hard to beat dividend-paying stocks -- they offer reliable income as well as stock-price appreciation.
Sanofi SA (NASDAQ: SNY) revealed a new early peek at data from breast cancer candidate amcenestrant, an oral selective estrogen receptor degrader. Data will be presented at the 2021 American Society of ...
These are two cheap stocks in an overvalued market.
Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting
Sanofi: Our vaccine could serve as an excellent booster shot
Thomas Triomphe, EVP at Sanofi Pasteur, discusses preliminary data from a Phase 2 trial for the drugmaker's Covid-19 vaccine developed in partnership with GlaxoSmithKline.
Based on promising interim data from a phase II study, Sanofi (SNY) plans to initiate a pivotal late-stage study on its adjuvanted vaccine candidate being developed in collaboration with Glaxo in the co...
Not convinced IP waiver rights will accelerate vaccine access: Sanofi Pasteur EVP
Thomas Triomphe discusses the results of its Covid-19 vaccine trial and the issue of IP wavier rights.
Sanofi (EPA: SAN) said on Monday its candidate COVID-19 vaccine that it developed with Britain's GlaxoSmithKline (LON: GSK) showed promising results in early-stage clinical trials, paving the way to mov...
GlaxoSmithKline PLC (LON:GSK) and Sanofi are planning to join the vaccine race well after their competitors as they pin their hopes on the need for boosters. The pair have received lukewarm market react...
GlaxoSmithKline PLC (LON:GSK) and Sanofi are planning to join the vaccine race well after their competitors as they pin their hopes on the need for boosters. The pair have received lukewarm market react...
A Phase 3 trial to test the vaccine's efficacy is expected to start in a matter of weeks, with the vaccine showing potential to be a booster shot.
Sanofi and GSK see positive interim results for their Covid vaccine in trials
CNBC's Charlotte Reed reports on the Sanofi-GSK Covid-19 vaccine showing a "strong immune response" in phase 2 trials.
Sanofi SA (NASDAQ: SNY) and its collaborating partner GlaxoSmithKline plc (NYSE: GSK) have reported "strong immune responses" in early tests of their COVID-19 vaccine, raising hopes it could join the fi...
News will offer some some relief for GSK chief Emma Walmsley, who has been under pressure from investor
GlaxoSmithKline PLC (LON:GSK) announced that the COVID-19 vaccine developed with French giant Sanofi demonstrated strong immune responses in mid-stage trials. The jab showed 95% to 100% seroconversion f...
GlaxoSmithKline PLC (LON:GSK) announced that the COVID-19 vaccine developed with French giant Sanofi demonstrated strong immune responses in mid-stage trials. The jab showed 95% to 100% seroconversion f...
You might want to add this international blue-chip stock to your portfolio.
It signals a big push toward curing a neurological disease with a massive market.
The companies have a promising RSV candidate.
Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research
PARIS and PALO ALTO, Calif., May 6, 2021 /PRNewswire/ -- Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine.
Sanofi SA (NASDAQ: SNY) stock climbed after its Q1 earnings beat earnings expectations and stuck to its full-year guidance, as well as reported progress on its delayed COVID-19 vaccine efforts. Earnings...
Sanofi's (SNY) Q1 earnings and sales beat estimates. Dupixent drives sales growth in the quarter.
Covid vaccine will be available by the end of 2021, says Sanofi CEO
Sanofi CEO Paul Hudson joins "Squawk on the Street" to discuss the company's Q1 results, the development of a vaccine for Covid and more.
Sanofi's first quarter boosted by eczema treatment and vaccines
CNBC's Charlotte Reed reports on Sanofi's first-quarter results which came in line with expectations, while the French pharmaceutical still works on its delayed Covid-19 vaccines.
Sanofi confirmed its 2021 targets after it posted stronger-than-expected first quarter results as sales of its star eczema treatment as well as flu and polio vaccines helped offset a dip in cough and co...
As the demand for mRNA-based COVID-19 vaccines persists, Sanofi SA (NASDAQ: SNY) has entered an agreement with Moderna Inc (NASDAQ: MRNA) to manufacture its COVID-19 vaccine in the U.S. The agreement ma...
The shots could be geared towards children, new variants or boosters.
Sanofi to manufacture up to 200 million doses of Moderna's Covid vaccine
Sanofi says it has entered into an agreement with Moderna to help bottle the company's coronavirus vaccine starting in September 2021. CNBC's Meg Tirrell reports.
BRIDGEWATER, N.J., April 26, 2021 /PRNewswire/ -- Sanofi has entered into an agreement with Moderna, under which Sanofi will help manufacture Moderna´s COVID-19 vaccine, supporting the COVID-19 pandemic...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces agreement with Sanofi for fill/finish manufacturing of the Moderna COVID-19 Vaccine in the U.S.
Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc's (NASDAQ: AZN) monoclonal antibody (mAb) nirsevimab has reached its primary endpoint in a Phase 3 trial, demonstrating protection against respiratory syncyti...
Boston-area biotech Replimune Group Inc. (NASDAQ:REPL) just boosted its executive lineup with a heavy hitter, and the market seems to like the addition.
About SNY
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescriptio... [Read more...]
| Industry Drug Manufacturers-General | |
| CEO Olivier Brandicourt | Employees 99,412 |
| Stock Exchange NASDAQ | Ticker Symbol SNY |
Financial Performance
In 2020, Sanofi's revenue was 37.37 billion, a decrease of -0.70% compared to the previous year's 37.63 billion. Earnings were 12.31 billion, an increase of 338.85%.
Analyst Forecasts
According to 7 analysts, the average rating for Sanofi stock is "Buy." The 12-month stock price forecast is 63.88, which is an increase of 18.74% from the latest price.